Recent Updates — CLVT
Clarivate Plc completed the previously announced sale of its Life Sciences and Healthcare business to an affiliate of Altaris, LLC on October 6, 2026. The transaction carries an aggregate purchase price of $600 million, structured as approximately $488.4 million in cash at closing (net of costs and working capital adjustments), a $75 million unsecured senior note, and $25 million in deferred cash consideration payable by January 31, 2028. Clarivate intends to use the proceeds for partial redemptions of its Senior Secured Notes due 2028 and Senior Notes due 2029. The divested unit is classified as discontinued operations, with a transition services agreement in place to support Altaris post-closing. Clarivate Plc operates in the information analytics industry.
Clarivate Plc completed the previously announced divestiture of its Life Sciences and Healthcare segment to an affiliate of Altaris, LLC. The transaction involves cash consideration of $500 million and an unsecured senior note with a principal amount of $75 million issued by the buyer, along with deferred consideration of $25 million payable upon completion of transition services or January 31, 2028. In connection with the closing, Henry Levy, Clarivate’s President for Life Sciences & Healthcare, terminated his employment under a separation agreement. The company intends to use proceeds to reduce debt and strengthen its balance sheet. Clarivate is a leading global provider of transformative intelligence solutions in academia, government, and intellectual property.
Clarivate Plc announced that its wholly-owned subsidiary, Clarivate Science Holdings Corporation, commenced a cash tender offer to purchase up to $75 million in aggregate principal amount of its outstanding 3.875% Senior Secured Notes due July 1, 2028. The company has $825 million of these notes outstanding. The offer expires on September 23, 2026, with settlement expected on September 25, 2026. Clarivate operates in the intellectual property and scientific intelligence industry.
Clarivate Plc announced on July 29, 2026, that Jonathan Collins resigned as Executive Vice President and Chief Financial Officer, effective August 7, 2026. The departure was voluntary and not due to disagreements with management or the Board. Michael Easton was appointed as his successor, effective August 8, 2026. Easton receives an initial annual base salary of $600,000, a target bonus opportunity equal to 100% of base salary, and a targeted long-term equity incentive grant valued at $2,000,000 for 2027. Additionally, he will receive a one-time promotion equity award valued at $750,000 on August 15, 2026. Clarivate Plc is a leading global provider of transformative intelligence, offering data, insights, analytics, and expert services in academia, intellectual property, and life sciences.
Clarivate Plc reported second quarter 2026 results on July 29, 2026, showing total revenues of $587.3 million and a net loss of $268.6 million, or $0.42 per diluted share. The net loss was primarily driven by a $221.7 million non-cash goodwill impairment charge associated with the divestiture of its Life Sciences & Healthcare segment. Adjusted net income was $123.1 million, or $0.19 per diluted share, and adjusted EBITDA was $247.2 million. The company reaffirmed its full-year 2026 outlook, projecting revenues between $2.30 billion and $2.42 billion and adjusted EBITDA between $980 million and $1.04 billion. Additionally, Clarivate announced the appointment of Michael Easton as Executive Vice President and Chief Financial Officer. The company operates in the intellectual property, scientific, and medical information industry.